BWBerend J. van Welzen

Berend J. van Welzen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Berend J. van Welzen has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Not Tuberculosis After All: The “Hare‐Raising Case” of Tularemia in a Patient With Advanced HIV Infection

    by J. X. Geerdink, B. J. Van Welzen

    We report a rare case of pneumonic tularemia in a person with an advanced HIV infection, in which a mediastinoscopy was ultimately required for microbiological confirmation. Serological testing remained negative. This case illustrates the extent to which pneumonic tularemia can mimic pulmonary tuberculosis and illustrates the limitations of serology in immunocompromised individuals. Clinicians should consider tularemia in the differential diagnosis of pulmonary disease with necrotizing lymphadenopathy, even in regions where the incidence is low.

  • Incidence of Community-acquired Pneumonia and Herpes Zoster in People With HIV Based on CD4 Count and Age in the Current Antiretroviral Therapy Era: A Longitudinal Cohort Study

    by Elsemieke Te Linde, Ferdinand W N M Wit, Berend J van Welzen, Abraham Goorhuis, Robert-Jan Hassing, Hanna K de Jong, Johanneke Kleinnijenhuis, Steven F L van Lelyveld, Els van Nood, Annelies Verbon, et al.

    Background: People with HIV (PWH) using antiretroviral therapy (ART) remain at increased risk for infections such as community-acquired pneumonia (CAP) and herpes zoster (HZ), for which vaccinations are recommended. However, these recommendations do not consider the combined effects of age, CD4 count, and duration of ART on infection risk. We assessed how these factors influence CAP and HZ incidence to better tailor vaccination strategies. Methods: We used data from a nationwide cohort study including all PWH aged ≥18 years in care between 2010 and 2023. All documented CAP and HZ episodes were included, and incidence rates were calculated per 1000 person-years of follow-up (PYFU), stratified by age, CD4 count, and ART duration. Results: Community-acquired pneumonia and herpes zoster incidence rates were highest in PWH with CD4 ≤ 200 cells/µL, ranging from 34 to 107/1000 PYFU for CAP and 9 to 63/1000 PYFU for HZ, depending on age. In those with CD4 ≥ 500 cells/µL and ≥1 year on ART, incidence rates ranged from 5 to 20/1000 PYFU for CAP and 4 to 5/1000 PYFU for HZ, depending on age. Conclusions: Incidence rates are the highest in PWH with CD4 counts ≤200 cells/µL and/or not on ART, whereas PWH with CD4 counts ≥500 and ≥1 year on ART have a risk of CAP and HZ comparable to that of the general population. These findings support aligning vaccine recommendations for PWH on long-term suppressive ART with immune reconstitution with those for the general population, while HIV-specific vaccination strategies may remain most relevant for individuals with virological failure and/or poor immune reconstitution.


  • Open Access

    Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review

    by Wendy J. Boschloo, Berend J. van Welzen

    The human immunodeficiency virus type 2 (HIV-2) is a particular subtype of HIV, which is endemic in West Africa and is characterized by a more indolent course than HIV-1. As people living with HIV-2 (PWH-2) are at risk for the development of acquired immunodeficiency syndrome and can transmit the virus, antiretroviral therapy is usually indicated. However, the optimal treatment of HIV-2 is unknown and historically the protease inhibitors (PIs) were a regular part of therapy. Nowadays, the use of integrase strand transfer inhibitors (INSTIs) in HIV-2 is increasing but the evidence supporting this approach is limited. In this narrative review, we outline the clinical data on the use of INSTI-containing antiretroviral therapy in HIV-2. We found that in the setting of treatment-naïve PWH-2, the use of INSTIs is successful, but also noted large heterogeneity in reported outcomes and that most cohorts are small with limited follow-up time. There is a lack of studies comparing the efficacy of INSTIs to other first-line options. For treatment-experienced PWH-2, the efficacy of INSTI is highly variable.


  • Open Access

    Underlying Neural Mechanisms of Cognitive Improvement in Fronto-striatal Response Inhibition in People Living with HIV Switching Off Efavirenz: A Randomized Controlled BOLD fMRI Trial

    by Patrick G. A. Oomen, Charlotte S. Hakkers, Joop E. Arends, Guido E. L. van der Berk, Pascal Pas, Andy I. M. Hoepelman, Berend J. van Welzen, Stefan du Plessis

    Introduction It is unclear whether neurotoxicity due to the antiretroviral drug efavirenz (EFV) results in neurocognitive impairment in people living with HIV (PLWH). Previously, we found that discontinuing EFV was associated with improved processing speed and attention on neuropsychological assessment. In this imaging study, we investigate potential neural mechanisms underlying this cognitive improvement using a BOLD fMRI task assessing cortical and subcortical functioning. Methods Asymptomatic adult PLWH stable on emtricitabine/tenofovirdisoproxil/efavirenz were randomly (1:2) assigned to continue their regimen (n = 12) or to switch to emtricitabine/tenofovirdisoproxil/rilpivirine (n = 28). At baseline and after 12 weeks, both groups performed the Stop-Signal Anticipation Task, which tests reactive and proactive inhibition (indicative of subcortical and cortical functioning, respectively), involving executive functioning, working memory, and attention. Behavior and BOLD fMRI activation levels related to processing speed and attention Z-scores were assessed in 17 pre-defined brain regions. Results Both groups had comparable patient and clinical characteristics. Reactive inhibition behavioral responses improved for both groups on week 12, with other responses unchanged. Between-group activation did not differ significantly. For reactive inhibition, positive Pearson coefficients were observed for the change in BOLD fMRI activation levels and change in processing speed and attention Z-scores in all 17 regions in participants switched to emtricitabine/tenofovir disoproxil/rilpivirine, whereas in the control group, negative correlation coefficients were observed in 10/17 and 13/17 regions, respectively. No differential pattern was observed for proactive inhibition. Conclusion Potential neural mechanisms underlying cognitive improvement after discontinuing EFV in PLWH were found in subcortical functioning, with our findings suggesting that EFV’s effect on attention and processing speed is, at least partially, mediated by reactive inhibition. Trial Registration Clinicaltrials.gov identifier [NCT02308332].


  • Reply to Buzón-Martín and Troya

    by Berend J Van Welzen, David Burger, Annemarie M J Wensing

    Berend J van Welzen, MD PhD, David Burger, PharmD PhD, Annemarie M J Wensing, MD PhD; Response to correspondence ‘Reasons against routine determination of plasm


  • Open Access

    Dynamics of Low-Level Viremia and Immune Activation after Switching to a Darunavir-Based Regimen

    by Arjen J. Stam, Ninée V. E. J. Buchholtz, Wouter F. W. Bierman, Reinout van Crevel, Andy I. M. Hoepelman, Mark A. A. Claassen, Heidi S. M. Ammerlaan, Berend J. van Welzen, Marjo E. E. van Kasteren, Steven F. L. van Lelyveld, et al.

    There is an ongoing debate regarding whether low-level viremia (LLV), in particular persistent LLV, during HIV treatment with optimal adherence originates from low-level viral replication, viral production, or both. We performed an observational study in 30 individuals with LLV who switched to a boosted darunavir (DRV)-based therapy. In-depth virological analyses were used to characterize the viral population and the (activity) of the viral reservoir. Immune activation was examined using cell-bound and soluble markers. The primary outcome was defined as the effect on HIV-RNA and was categorized by responders (50 cp/mL). At week 24, 53% of the individuals were considered responders, 40% non-responders, and 7% could not be assigned. Sequencing showed no evolution or selection of drug resistance in the non-responders. Production of defective virus with mutations in either the protease (D25N) or RT active site contributed to persistent LLV in two individuals. We show that in about half of the study participants, the switch to a DRV-based regimen resulted in a viral response indicative of ongoing low-level viral replication as the cause of LLV before the switch. Our data confirm that in clinical management, high genetic barrier drugs like DRV are a safe choice, irrespective of the source of LLV.


  • Top Cited Papers
    Open Access

    Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis

    by Berend J van Welzen, Steven F L Van Lelyveld, Gerjanne Ter Beest, Jet H Gisolf, Suzanne E Geerlings, Jan M Prins, Gitte Van Twillert, Cees Van Nieuwkoop, Marc Van der Valk, David Burger, et al.

    Background: Long-acting (LA) injectable therapy with cabotegravir (CAB) and rilpivirine (RPV) is currently used as maintenance treatment for human immunodeficiency virus type 1, and has a low risk for virological failure (VF). Although the risk is low, the circumstances and impact of VF in the real-world setting merit further evaluation. Methods: We performed an in-depth clinical, virological, and pharmacokinetic analysis on the reasons behind and the impact of VF during LA CAB/RPV therapy in 5 cases from the Netherlands. Genotypic resistance testing was performed after the occurrence of VF, and drug plasma (trough) concentrations were measured after VF was established and on any other samples to assess on-treatment drug levels. CAB and RPV drug levels that were below the first quartile of the population cutoff (≤Q1) were considered to be low. Results: Five cases who were eligible for LA CAB/RPV experienced VF despite a low predicted risk at baseline. Genotypic resistance testing revealed extensive selection of nonnucleoside reverse transcriptase inhibitor–associated mutations in all cases, and integrase strand transfer inhibitor mutations in 4 cases. All cases displayed low drug levels of either CAB, RPV, or both during the treatment course, likely contributing to the occurrence of VF. In 3 cases, we were able to identify the potential mechanisms behind these low drug levels. Conclusions: This is the first in-depth multiple case analysis of VF on LA CAB/RPV therapy in a real-world setting. Our observations stress the need to be aware for (evolving) risk factors and the yield of a comprehensive clinical, virological, and pharmacokinetic approach in case of failure.


  • Open Access

    Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts

    by Stefan Esser, Jason Brunetta, Alexy Inciarte, Itzchak Levy, Antonella D'ARminio Monforte, John S. Lambert, Berend van Welzen, Katsuji Teruya, Marta Boffito, Chun‐Eng Liu, et al.

    Background: Real‐world evidence is an essential component of evidence‐based medicine. The aim of the BICSTaR (BICtegravir Single Tablet Regimen) study is to assess effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in antiretroviral treatment‐naïve (TN) and treatment‐experienced (TE) people with HIV.Methods: BICSTaR is a prospective, observational cohort study. Participants (≥18 years) are being followed for 24 months. A pooled analysis is presented at 12 months, with the primary endpoint of effectiveness (HIV‐1 RNA p < 0.001) in TN participants and 13 cells/μL (p = 0.014) in TE participants; median CD4/CD8 ratios increased by 0.30 and 0.03, respectively (both p < 0.001). Persistence was high at 12 months (TN, 97%; TE, 95%). No resistance to B/F/TAF emerged. Study drug‐related adverse events occurred in 13% of participants through 12 months, leading to B/F/TAF discontinuation in 6%.Conclusions: The findings of this study provide robust real‐world evidence to support the broad use of B/F/TAF in both TN and TE people with HIV.